Equities research analysts forecast that Allergan PLC. (NYSE:AGN) will announce earnings per share (EPS) of $4.76 for the current fiscal quarter, according to Zacks Investment Research. Nineteen analysts have provided estimates for Allergan PLC.’s earnings. The lowest EPS estimate is $4.51 and the highest is $4.94. Allergan PLC. posted earnings of $3.90 per share in the same quarter last year, which would suggest a positive year over year growth rate of 22.1%. The firm is expected to report its next earnings report on Wednesday, February 14th.

According to Zacks, analysts expect that Allergan PLC. will report full-year earnings of $16.20 per share for the current year, with EPS estimates ranging from $15.97 to $16.39. For the next financial year, analysts forecast that the firm will report earnings of $17.20 per share, with EPS estimates ranging from $15.00 to $18.38. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Allergan PLC..

Allergan PLC. (NYSE:AGN) last posted its earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.06 by $0.09. Allergan PLC. had a positive return on equity of 7.86% and a negative net margin of 47.27%. The firm had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the prior year, the company earned $3.32 EPS. Allergan PLC.’s revenue was up 11.4% on a year-over-year basis.

Several analysts recently issued reports on the company. Citigroup Inc. reiterated a “buy” rating and issued a $280.00 price target on shares of Allergan PLC. in a report on Wednesday, September 20th. Piper Jaffray Companies set a $227.00 target price on Allergan PLC. and gave the company a “hold” rating in a research note on Friday, October 6th. Deutsche Bank AG set a $251.00 price target on Allergan PLC. and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Royal Bank Of Canada reissued a “buy” rating and issued a $285.00 target price on shares of Allergan PLC. in a report on Wednesday, September 6th. Finally, Wells Fargo & Company set a $276.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Friday, October 13th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $246.73.

TRADEMARK VIOLATION WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/03/zacks-analysts-expect-allergan-plc-agn-to-announce-4-76-earnings-per-share.html.

Several hedge funds have recently added to or reduced their stakes in AGN. Cipher Capital LP acquired a new stake in shares of Allergan PLC. in the 1st quarter valued at $853,000. Hugh Johnson Advisors LLC lifted its position in Allergan PLC. by 3.5% during the 1st quarter. Hugh Johnson Advisors LLC now owns 10,042 shares of the company’s stock worth $2,399,000 after acquiring an additional 340 shares during the last quarter. Atlantic Trust Group LLC lifted its position in Allergan PLC. by 17.7% during the 1st quarter. Atlantic Trust Group LLC now owns 644,643 shares of the company’s stock worth $154,019,000 after acquiring an additional 97,079 shares during the last quarter. Sandy Spring Bank lifted its position in Allergan PLC. by 5.5% during the 1st quarter. Sandy Spring Bank now owns 10,120 shares of the company’s stock worth $2,417,000 after acquiring an additional 530 shares during the last quarter. Finally, Schroder Investment Management Group lifted its position in Allergan PLC. by 133.3% during the 1st quarter. Schroder Investment Management Group now owns 417,948 shares of the company’s stock worth $100,225,000 after acquiring an additional 238,796 shares during the last quarter. 82.02% of the stock is owned by institutional investors and hedge funds.

Shares of Allergan PLC. (NYSE:AGN) traded down $1.85 on Friday, hitting $175.38. The company had a trading volume of 9,046,067 shares, compared to its average volume of 5,440,519. The firm has a market capitalization of $58.33 billion, a PE ratio of 11.37 and a beta of 1.13.

Allergan PLC. announced that its board has initiated a stock repurchase plan on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.60%. The ex-dividend date of this dividend is Thursday, November 16th. Allergan PLC.’s payout ratio is presently -12.44%.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get a free copy of the Zacks research report on Allergan PLC. (AGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.